Three-dose-cohort designs in cancer phase I trials

Statistics in Medicine

Volumn 27, Issue 12, 2008, Pages 2070-2093

  Huang, Bo ^a   Chappell, Rick ^b  

^a University of Wisconsin   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cancer phase I trials; Continual reassessment method; Maximum tolerable dose; Multiple dosing

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCURACY; ARTICLE; BAYES THEOREM; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUAL REASSESSMENT METHOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SAFETY; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; MAXIMUM TOLERATED DOSE; PARAMETRIC TEST; PHASE 1 CLINICAL TRIAL; SAMPLE SIZE; SIMULATION; TIME MANAGEMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 44649119909     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3054     Document Type: Article

References (16)

1. Storer BE. Design and analysis of Phase I clinical trials. Biometrics 1989 45:925-937.
2. Whitehead J. Bayesian decision procedures with application to dose-finding studies. International Journal of Pharmaceutical Medicine 1997; 11:201-208.
3. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for Phase I clinical trials in cancer. Biometrics 1990; 46:33-48.
4. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for Phase I studies. Statistics in Medicine 1995; 14:1149-1161.
5. Faries D. Practical modifications of the continual reassessment method for Phase I cancer clinical trials. Journal of Biopharmaceutical Statistics 1994; 4:147-164.
6. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics 1996; 52:673-684.
7. Schneiderman MA. How can we find an optimal dose? Toxicology and Applied Pharmacology 1965; 7:44-53.
8. Horstmann EBA, McCabe MS et al. Risks and benefits of Phase 1 oncology trials, 1991 through 2002. New England Journal of Medicine 2005 352:895-904.
9. Berger JO. Prior information and subjective probability, Chapter 3. Statistical Decision Theory and Bayesian Analysis. Springer: New York, 1980; 74-117.
10. Aitkin M. Posterior Bayes factors. Journal of the Royal Statistical Society, Series L 1991; 53:111-142.
11. Chevret S. The continual reassessment method in cancer Phase I trials: a simulation study. Statistics in Medicine 1993; 12:1093-1108.
12. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon R. A comparison of two Phase I trial designs. Statistics in Medicine 1994; 13:1799-1806.
13. Storer BE. Phase I clinical trials. Encyclopedia of Biometrics. Wiley: New York, 1998.
14. Cheung YK, Chappell R. A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics 2002; 58:671-674.
15. Shen LZ, O'Quigley J. Consistency of continual reassessment method under model misspecification. Biometrika 1996; 83:395-405.
16. Cheung YK. Coherence principles in dose-finding studies. Biometrika 2005; 92:863-873.